Iterum Therapeutics Plc

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous branded penem available. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Iterum Therapeutics progresses with sulopenem, faces regulatory challenges

Iterum Therapeutics (ITRM) showcased progress in key areas like FDA interactions, patent approvals, and maintaining a strong financial position.
While challenges exist in regulatory approval and funding, the company's strategic vision and commitment to growth offer opportunities for success.
Overall, Iterum's focus on advancing sulopenem for uncomplicated UTIs and engaging with the FDA reflects a promising trajectory for future growth.

Iterum Therapeutics reports improved Q3 performance with ORLYNVAH FDA approval

Iterum Therapeutics showed improved financials with lower expenses and a better net loss.
ORLYNVAH's FDA approval and market exclusivity offer growth potential in addressing UTIs.
Challenges lie in maintaining market exclusivity, international expansion, and strategic partnerships.
Opportunities include leveraging ORLYNVAH's approval, expanding internationally, and forming key partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.

DUBLIN, Ireland and CHICAGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that Corey Fishman, Chief Executive Officer, and Judy Matthews, Chief Financial Officer, will provide a company overview and business update at the H.C. Wainwright 24th Annual Hybrid Global Investment Conference at 12:00pm(ET) on Wednesday, September 14, 2022. Management will also host investor meetings on September 13-14, 2022.

Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

A 1-for-15 reverse split of Iterum Therapeutics (ITRM) shares have gone into effect. These are the details.

Iterum Therapeutics (ITRM) Stock: 1-For-15 Reverse Split Goes Into Effect

DUBLIN, Ireland and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, announced today that it will effect a 1-for-15 reverse share split of its outstanding ordinary shares at 5.00 p.m. Eastern Time on August 17, 2022, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on August 18, 2022.

Iterum Therapeutics Announces Date of 1-for-15 Reverse Share Split

--Enrollment in Registration Trial for uUTI to Begin Q4 2022-- --Cash Runway into 2024--

Iterum Therapeutics Reports Second Quarter 2022 Financial Results

Iterum Therapeutics plc (NASDAQ: ITRM) has agreed with the FDA under the special protocol assessment (SPA) process on the design, endpoints, and statistical analysis of a Phase 3 trial for oral sulopenem etzadroxil-probenecid for uncomplicated urinary tract infections. The pivotal.

Iterum Therapeutics Shares Are Surging - Read Why

Iterum Therapeutics (ITRM) stock is taking off on Monday as investors react to news of a clinical trial agreement with the FDA. The post Why Is Iterum Therapeutics (ITRM) Stock Up 73% Today?

Why Is Iterum Therapeutics (ITRM) Stock Up 73% Today?

Agile Therapeutics

RedHill Biopharma

T2 Biosystems

More penny stocks to watch under $1 The post Penny Stocks To Buy Now? 7 Hot Stocks Under $1 To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy Now? 7 Hot Stocks Under $1 To Watch

--SPA supports protocol for Phase 3 Clinical Trial of Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections-- --Clinical Trial Expected to Begin Enrollment in Q4 2022--

Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA

DUBLIN, Ireland and CHICAGO, July 06, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has granted a non-statutory share option to purchase an aggregate of 10,000 ordinary shares of the Company as an inducement to a newly hired employee. This grant was awarded pursuant to the Nasdaq inducement grant exception as a component of new hire employment compensation.

Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

-General Alignment with FDA on Key Aspects of Design of Proposed Additional Clinical Trial-  -Cash Runway into 2024-

Iterum Therapeutics Reports First Quarter 2022 Financial Results

DUBLIN, Ireland and CHICAGO, May 11, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced it met with the US Food and Drug Administration (“FDA”) on May 5, 2022, to discuss its proposed plan to conduct one additional Phase 3 clinical trial to support the potential resubmission of the Company's new drug application (“NDA") for oral sulopenem etzadroxil-probenecid (“oral sulopenem”) for the treatment of uncomplicated urinary tract infections (“uUTI”).

Iterum Therapeutics Provides Regulatory Update

DUBLIN, Ireland and CHICAGO, April 25, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced two poster presentations at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 23-26, 2022 in Lisbon, Portugal.

Iterum Therapeutics Presented Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases

Iterum Therapeutics plc (ITRM) CEO Corey Fishman on Q4 2021 Results - Earnings Call Transcript

- -Registration Trial for uUTI Planned in Second Half of 2022- - - -Cash Runway into 2024-- --Company to host conference call today at 8:30am ET--

Iterum Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Phunware Inc

Senseonics Holdings

Why investors are watching these penny stocks right now The post Hot Penny Stocks to Watch in Early February 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Watch in Early February 2022

DUBLIN, Ireland and CHICAGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the appointment of Sailaja Puttagunta, M.D., to the newly created position of Chief Medical Officer, where she will oversee global clinical development and regulatory initiatives for Iterum.

Iterum Therapeutics Appoints Sailaja Puttagunta, MD as Chief Medical Officer

Kosmos Energy

Transocean

Are these Reddit penny stocks on your watchlist right now? The post 3 Reddit Penny Stocks to Watch in December 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Reddit Penny Stocks to Watch in December 2021

Iterum Therapeutics PLC (ITRM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Iterum Therapeutics PLC (ITRM) Could Find Support Soon, Here's Why You Should Buy the Stock Now

Iterum Therapeutics plc (ITRM) CEO Corey Fishman on Q3 2021 Results - Earnings Call Transcript

- -Type B meeting with FDA requested to affirm design for additional Phase 3 trial needed for resubmission of NDA for Oral Sulopenem-- --Cash Runway into 2024--    --Iterum to host conference call today at 8:30am ET--

Iterum Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

Electrameccanica

China Rapid Finance

SurgePays

Are these penny stocks on your watchlist right now? The post Top Penny Stocks For Your List Today?

Top Penny Stocks For Your List Today? Check These 4 Out

DUBLIN, Ireland and CHICAGO, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2021 financial results before the open of the U.S. financial markets on Friday, November 12, 2021. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business.

Iterum Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on November 12, 2021

Camber Energy

Nxt-ID

Looking for penny stocks to watch right now? Check these three out The post Hot Penny Stocks You Need to Know About Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks You Need to Know About Right Now

New York, New York--(Newsfile Corp. - October 4, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Iterum Therapeutics Plc ("Iterum") (NASDAQ: ITRM) between November 30, 2020 and July 23, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=20109&wire=5

ITRM LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Iterum Therapeutics Plc

New York, New York--(Newsfile Corp. - October 4, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Iterum Therapeutics Plc (NASDAQ: ITRM) alleging that the Company violated federal securities laws.Class Period: November 30, 2020 and July 23, 2021Lead Plaintiff Deadline: October 4, 2021No obligation or cost to you.Learn more about your recoverable losses in ITRM:https://www.kleinstocklaw.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?id=20099&from=5

ITRM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2021 in the Class Action Filed on Behalf of Iterum Therapeutics Plc Limited Shareholders

News for Iterum Therapeutics Plc Stock (ITRM)